Alentis Therapeutics AG

5 trials 3 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

2 Completed trials

10 Countries active

7 Unique IMPs

100% Results reported

Phase II

Phase I (Other)

Phase I (FiH)

Phase II: 1 Phase I (Other): 1 Phase I (FiH): 3

Oversight events:

7 temporary halts across 1 trial

View oversight register →

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Glomerulonephritis rapidly progressive 1 Squamous cell carcinoma of head and neck 1 Hepatic fibrosis 1

Top IMPs

ALE.C04 1 ALE.P02 1 ALE.P03 1 LIXUDEBART 1 PEMBROLIZUMAB 1

All trials

5 total

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients with Selected CLDN1+ Solid Tumors Recruiting

2024-515459-39-00 Phase I (FiH) 3 countries ALE.P02
A Study to test ALE.P03 in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors Recruiting

2025-521441-24-00 Phase I (FiH) 4 countries ALE.P03
REscue of Nephrons with ALe.F02 (RENAL F02) Recruiting

2022-502184-38-00 Phase II 7 countries LIXUDEBART
FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC Ended

2023-505145-93-00 Phase I (FiH) 3 countries ALE.C04; PEMBROLIZUMAB
A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients with Advanced Liver Fibrosis and/… Ended

2024-516455-40-00 Phase I (Other) 2 countries

Showing 1–5 of 5 trials

← All sponsors A–Z